Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on...
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
